Humoral immune response to thymidylate synthase in colon cancer patients after 5-FU chemotherapy

详细信息    查看全文

• 作者：Yuriy V. Shebzukhov ; Ekaterina P. Koroleva ; Svetlana V. Khlgatian ; Maria A. Lagarkova ; Andrey A. Meshcheryakov ; Mikhail R. Lichinitser ; Julia Karbach ; Elke Jager ; Dmitry V. Kuprash and Sergei A. Nedos
• 刊名：Immunology Letters
• 出版年：2005
• 出版时间：2005
• 年：2005
• 卷：100
• 期：1
• 页码：88-93
• 全文大小：230 K

文摘

Summary

Thymidylate synthase (TYMS), the critical enzyme for DNA synthesis and a target for chemotherapy, was recently characterized as an oncogene and a potential target for specific immunotherapy. Here we report TYMS-specific antibody response in a fraction of colon cancer patients. Humoral immune response to TYMS is induced by chemotherapy using TYMS inhibitors, such as 5-fluorouracil (5-FU), and may be associated with tumor burden. Therefore, TYMS may serve as a useful serological biomarker for monitoring the course of disease and treatment in cancer patients.